Oaktree Specialty Lending Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oaktree Specialty Lending Corporation on August 2, 2024. The report details a material definitive agreement entered into on the same date regarding the company's equity distribution capabilities.
Key Financial Metrics
This filing does not contain periodic financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the increase in the company's authorized equity offering capacity.
- Equity Offering Capacity Increase: $175.0 million
- New Aggregate Offering Limit: $300.0 million
- Securities Involved: Common stock, par value $0.01 per share (Trading Symbol: OCSL)
Material Changes
On August 2, 2024, the Company entered into an amendment to its existing Equity Distribution Agreement, originally dated February 7, 2022, and previously amended in 2023. This amendment increases the maximum amount of common stock shares that may be offered and sold through the designated placement agents (Keefe, Bruyette & Woods, Inc., Citizens JMP Securities, LLC, Jefferies LLC, and Raymond James & Associates, Inc.) by $175.0 million.
Outlook and Management Commentary
The filing indicates the Company's intent to utilize an "at-the-market" offering mechanism to raise capital from time to time. The offering is made pursuant to an effective shelf registration statement on Form N-2 (Registration No. 333-269628). The filing explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the full text of the Third Amendment to the Equity Distribution Agreement (Exhibit 1.1) for specific terms and conditions.
- Review the Company's most recent quarterly or annual report (10-Q or 10-K) for current liquidity, debt levels, and portfolio performance, as this 8-K does not provide those figures.
- Confirm the status of the shelf registration statement (No. 333-269628) and any subsequent prospectus supplements.
- Monitor future filings for actual sales of shares under the expanded $300.0 million limit.